FIELD: medicine.
SUBSTANCE: present invention refers to immunology. Disclosed is an isolated antibody and its antigen-binding fragment which specifically bind to glucocorticoid-induced TNF receptor (GITR); as well as compositions, including a pharmaceutical composition and method of enhancing immune response in a human. Provided is an isolated nucleic acid coding light chain and heavy chain antibody or its antigen-binding fragment; vector, host cell and method of producing disclosed antibody or its antigen-binding fragment.
EFFECT: antibodies according to present invention are capable of increasing activity of human GITR and can find further application of combination therapy of various diseases.
30 cl, 2 dwg, 9 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-GITR ANTIBODIES | 2010 |
|
RU2646139C1 |
| HUMAN MONOCLONAL ANTIBODIES AGAINST PROGRAMMED DEATH 1 (PD-1) PROTEIN AND CANCER TREATMENT METHOD USING ANTI-PD-1-ANTIBODIES SEPARATELY OR COMBINED WITH OTHER IMMUNOTHERAPEUTIC AGENTS | 2013 |
|
RU2599417C2 |
| NOVEL ANTIBODIES | 2008 |
|
RU2490277C2 |
| ANTIBODIES TO PROGRAMMED CELL DEATH PROTEIN 1 | 2018 |
|
RU2812915C2 |
| INTERLEUKIN-13-BINDING PROTEINS | 2012 |
|
RU2605327C2 |
| ANTI-PTK7 ANTIBODY-DRUG CONJUGATES | 2015 |
|
RU2708075C2 |
| ANTI-αvβ8 ANTIBODIES AND COMPOSITIONS AND THEIR USE | 2019 |
|
RU2812478C2 |
| INTERLEUKIN-13-BINDING PROTEINS | 2016 |
|
RU2650767C2 |
| HUMAN MONOCLONAL ANTIBODIES AGAINST PROGRAMMED DEATH 1 (PD-1) PROTEIN AND CANCER TREATMENT METHOD USING ANTI-PD-1-ANTIBODIES SEPARATELY OR COMBINED WITH OTHER IMMUNOTHERAPEUTIC AGENTS | 2006 |
|
RU2406760C2 |
| HUMAN MONOCLONAL ANTIBODIES SPECIFIC FOR PROGRAMMED CELL DEATH 1 (PD1) PROTEIN AND METHODS OF TREATING CANCER WITH USING ANTI-PD1 ANTIBODIES EITHER INDIVIDUALLY, OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTIC AGENTS | 2006 |
|
RU2494107C2 |
